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Sir,
We appreciate the opportunity to give a comment on the
interesting letter by Ferretti et al in this issue. The need of a
comprehensive combined analysis of multiple germline poly-
morphisms in genes involved in the folate metabolism and
expression of these genes and their proteins in view of
corresponding expression data is demanded by the authors for
prediction of efficacy and toxicity of 5-fluorouracil (5-FU)-based
chemotherapy. We agree to this statement. Our group conducted a
combined analysis of polymorphisms of TS and MTHFR (folate
pathway) as well as polymorphisms of GSTP1, ERCC1 and ERCC2,
enzymes with potential impact on cisplatin efficacy (Goekkurt
et al, 2006). The finding that our combined analyses of TS 50 and
GSTP1 genotypes resulted in a significant association with
response and overall survival in our patient population (advanced
gastric cancer patients treated with 5-FU/cisplatin as first-line
palliative treatment) encourages for combined and more compre-
hensive analyses of more than one polymorphism in more than
one metabolic or regulatory pathway. There are examples in the
literature already for comprehensive genotype analyses for gastric
cancer and also for colorectal cancer (Stoehlmacher et al, 2004;
Ruzzo et al, 2006). We are aware of the fact that our study is
limited to few genotypes, and, as mentioned in our discussion,
more genetic factors (polymorphisms) should be considered for
the explanation of inter-individual variability in chemotherapy
response, and more so in case of application of combination
chemotherapy. Therefore, we mentioned our ongoing prospective
study in a large phase III trial in advanced gastric cancer including
a panel of at least 26 polymorphisms in genes of platinum and
folate metabolism as well as in DNA-repair genes. However,
performing such comprehensive analyses must take into account
the relevance of certain polymorphisms for the clinical setting, for
example very low frequencies of variant genotypes (e.g. dihydro-
pyrimidine dehydrogenase (DPD) polymorphism). Furthermore, a
functional impact of a certain polymorphism on gene/protein
expression or protein function should be evaluated as clear as
possible prior to entering a translational study (e.g. unclear
functionality of orotate phosphoribosyl transferase (OPRT) or
uridine monophosphate kinase (UMPK) polymorphisms).
In contrast to gene/protein expression data, which always
display a cross-section of a dynamic process, genotypes remain
stable and can be determined easily either from normal as well as
from tumour tissue. As tumour tissue is not always available,
especially in the advanced tumour setting, genotyping of normal
host cells (e.g. leucocytes) remain easily accessible and cost-
effective at any time of treatment. Despite, an existing controver-
sially discussion about the value of host vs tumour genotyping for
cancer pharmacogenetic studies, the use of germline DNA is
validated with a minor source of error due to little discrepancies
between the host and tumour genome (Marsh et al, 2005). The use
of expression data, if available, may be very helpful for
pharmacogenomic studies in cancer. However, expression data
do not provide information about alteration of protein function,
for example, due to germline polymorphisms or tumour-specific
mutations. Of course if applicable, tumour-specific mutations
should be taken into account in pharmacogenetic analyses as it is
the case in non-small-cell lung cancer and in the use of inhibitors
of EGFR.
In conclusion, we agree with the demand for a comprehensive
combined analysis in cancer pharmacogenetic studies including
several relevant and reliable factors. So far, the process of
identifying the most important factors is still ongoing and reveals
controversial results. Maybe even more important, there are
currently no sufficient statistical models to incorporate the
different impact of frequency and functionality of a single
polymorphism for the prediction value of the whole analysis. For
most polymorphisms, its functional significance is not even clear.
Especially before that background, we have to incorporate as much
information in our pharmacogenetic analyses as possible and
perform true comprehensive studies.
If we focus on TS polymorphisms, we note that there are several
divergent observations being published so far. In a study by
Jakobsen et al (2005) in advanced colorectal cancer, for example,
TS 50-UTR 3R/3R genotype carriers showed better clinical Published online 17 October 2006
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www.bjcancer.comoutcomes than patients with TS 50-UTR 2R/2R genotypes. These
findings are not in agreement with the hypothesis that the 3R allele
is correlated with higher TS mRNA levels and worse clinical
outcome. However, the authors did not include the G/C SNP
located within the 3R allele which might be an explanation for their
opposite findings. Our data in contrast are in line with several
observations by other investigators. Recently, in a prospective
setting with a large patient cohort (n¼175), Ruzzo et al (2006)
could demonstrate the same impact of TS 50-UTR and GSTP1
polymorphisms than we did on clinical outcome in advanced
gastric cancer patients. At least for few genetic markers, such as TS
polymorphisms, a lot of data with respect to cancer pharmacoge-
netic studies exist and prospective validation and evaluation of
their potential as stratification parameter is ongoing.
The TS example shows that we will constantly learn in
pharmacogenetics and that it needs large and comprehensive
studies to find the ‘truth’ in order to develop robust tests for the
clinical setting.
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